Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01475981 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects
A Phase 1 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT01475981 is a Phase 1 study that has completed, run by Akros Pharma. The registered enrollment target is 70 participants.
The verdict
NCT01475981, a Phase 1 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the safety, tolerability and pharmacokinetics of ascending single oral doses of JTK-853 administered under fasted or fed conditions in healthy male subjects.
Interventions
- DRUG JTK-853 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2010-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01475981
The ClinicalTrials.gov registry entry for NCT01475981 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JTK-853 or Placebo is the first listed.
NCT01475981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01475981 about?
NCT01475981 is a clinical study titled "Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects". The purpose of this study was to determine the safety, tolerability and pharmacokinetics of ascending single oral doses of JTK-853 administered under fasted or fed conditions in healthy male subjects.
What is the current status of trial NCT01475981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2010-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT01475981?
The interventions under investigation include: JTK-853 or Placebo (DRUG).
Who is sponsoring clinical trial NCT01475981?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.